NIH-12848 100 mg | 99.84%
TargetMol
NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
More Information Supplier PageNIH-12848
Search Results
(RS)-MCPG 100 mg | Purity Not Available
TargetMol
(RS)-MCPG is a non-selective group I/II metabotropic glutamate receptor antagonist.
More Information Supplier Page(RS)-MCPG
E4CPG 5 mg | 99.96%
TargetMol
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier PageE4CPG
E4CPG 50 mg | 99.96%
TargetMol
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier PageE4CPG
E4CPG 25 mg | 99.96%
TargetMol
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier PageE4CPG
E4CPG 10 mg | 99.96%
TargetMol
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier PageE4CPG
E4CPG 100 mg | 99.96%
TargetMol
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
More Information Supplier PageE4CPG
Naloxegol oxalate 5 mg | 99.82%
TargetMol
Naloxegol oxalate is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation.
More Information Supplier PageNaloxegol oxalate
Naloxegol oxalate 50 mg | 99.82%
TargetMol
Naloxegol oxalate is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation.
More Information Supplier PageNaloxegol oxalate
(RS)-MCPG 10 mg | Purity Not Available
TargetMol
(RS)-MCPG is a non-selective group I/II metabotropic glutamate receptor antagonist.
More Information Supplier Page(RS)-MCPG
